Klepser Michael E
Ferris State University, Big Rapids, and Borgess Medical Center, Kalamazoo, Michigan, USA.
Curr Opin Infect Dis. 2004 Apr;17(2):109-12. doi: 10.1097/00001432-200404000-00007.
The purpose of this review is to summarize modern data pertaining to the use of aerosolized antimicrobials for the treatment of and prophylaxis against pulmonary infections.
Few recent publications have examined the safety and efficacy of nebulized antibiotics. Two well conducted trials have been published that describe the utility of tobramycin solution for inhalation among cystic fibrosis patients. A couple of good reviews have also been published that have summarized the use of aerosolized antibiotics in other patient populations.
Data regarding this topic are scarce. At this time, data support the use of aerosolized tobramycin solution for inhalation in cystic fibrosis patients infected or colonized by Pseudomonas aeruginosa. Apart from this situation, widespread aerosolized administration of other agents in cystic fibrosis and non-cystic fibrosis patient populations should not be advocated.
本综述旨在总结有关雾化抗菌药物用于治疗和预防肺部感染的现代数据。
近期很少有出版物研究雾化抗生素的安全性和有效性。已发表了两项精心开展的试验，描述了妥布霉素吸入溶液在囊性纤维化患者中的效用。也发表了几篇不错的综述，总结了雾化抗生素在其他患者群体中的应用。
关于这一主题的数据很少。目前，数据支持在感染铜绿假单胞菌或被其定植的囊性纤维化患者中使用雾化妥布霉素吸入溶液。除此之外，不应提倡在囊性纤维化和非囊性纤维化患者群体中广泛雾化使用其他药物。
